PharmaSGP Holding Past Earnings Performance
Past criteria checks 4/6
PharmaSGP Holding's earnings have been declining at an average annual rate of -2.9%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 12.1% per year. PharmaSGP Holding's return on equity is 41.2%, and it has net margins of 16.2%.
Key information
-2.9%
Earnings growth rate
-2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 12.1% |
| Return on equity | 41.2% |
| Net Margin | 16.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings
May 06
Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio
Mar 02PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04Revenue & Expenses BreakdownBeta
How PharmaSGP Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 101 | 16 | 51 | 0 |
| 30 Sep 23 | 98 | 15 | 51 | 0 |
| 30 Jun 23 | 94 | 14 | 48 | 0 |
| 31 Mar 23 | 89 | 13 | 46 | 0 |
| 31 Dec 22 | 86 | 12 | 44 | 0 |
| 30 Sep 22 | 83 | 11 | 64 | 0 |
| 30 Jun 22 | 81 | 11 | 42 | 0 |
| 31 Mar 22 | 74 | 11 | 46 | 0 |
| 31 Dec 21 | 65 | 11 | 36 | 0 |
| 30 Sep 21 | 61 | 8 | 36 | 0 |
| 30 Jun 21 | 56 | 8 | 34 | 0 |
| 31 Mar 21 | 59 | 9 | 36 | 0 |
| 31 Dec 20 | 63 | 11 | 35 | 0 |
| 30 Sep 20 | 65 | 16 | 31 | 0 |
| 30 Jun 20 | 65 | 17 | 31 | 0 |
| 31 Mar 20 | 64 | 17 | 22 | 0 |
| 31 Dec 19 | 63 | 17 | 30 | 0 |
| 31 Dec 18 | 61 | 15 | 29 | 0 |
| 31 Dec 17 | 53 | 12 | 28 | 0 |
Quality Earnings: PSG has high quality earnings.
Growing Profit Margin: PSG's current net profit margins (16.2%) are higher than last year (13.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PSG's earnings have declined by 2.9% per year over the past 5 years.
Accelerating Growth: PSG's earnings growth over the past year (37.2%) exceeds its 5-year average (-2.9% per year).
Earnings vs Industry: PSG earnings growth over the past year (37.2%) exceeded the Pharmaceuticals industry 3%.
Return on Equity
High ROE: Whilst PSG's Return on Equity (41.25%) is outstanding, this metric is skewed due to their high level of debt.